Startup profile · funding coverage
Sava Technologies funding, valuation and investors
A wearable microsensor platform for continuous glucose and multi-biomarker monitoring.
Keep track of Sava Technologies
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B
$36M · October 9, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$63M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series b · London, United Kingdom
Investors in latest funding
Lead: Ascensia Diabetes Care
Other: Balderton Capital , Norrsken VC , Simplyhealth Ventures , JamJar Investments , Pentland Ventures
Overview
Sava Technologies develops a wearable microsensor platform that continuously measures biomarkers just beneath the skin, beginning with glucose monitoring.
Why Sava Technologies is interesting
Sava pairs a shorter glucose microsensor with an established diabetes-distribution partner. Its Series B is tied directly to manufacturing scale-up, a pivotal clinical study and a planned European launch, making commercialization execution more important than another prototype milestone.
Product & use cases
Sava’s first product is an investigational wearable continuous glucose monitor using a proprietary microsensor that measures interstitial glucose just beneath the skin. The underlying platform is intended to expand to other biomarkers over time.
- Continuous glucose monitoring for people with diabetes.
- Non-adjunctive glucose readings for insulin-dosing decisions, subject to regulatory approval.
- Future continuous monitoring of additional biomarkers.
Key facts
- Raised a $36 million Series B led by Ascensia Diabetes Care on October 9, 2026.
- Signed a European commercialization and distribution agreement with Ascensia.
- Plans a pivotal clinical study and targets CE approval for non-adjunctive use within 18 to 24 months.
Funding history (newest first)
Series B
2026-10-09 $36M- Ascensia Diabetes Care (lead)
- Balderton Capital (participant)
- Norrsken VC (participant)
- Simplyhealth Ventures (participant)
- JamJar Investments (participant)
- Pentland Ventures (participant)
Series A
2025-07-31 $19M- Balderton Capital (lead)
- Pentland Ventures (lead)
- Norrsken VC (participant)
- JamJar Investments (participant)
- True (participant)
- Italian Founders Fund (participant)
- Athletico Ventures (participant)
- Exceptional Ventures (participant)
Investors in our directory
Funds linked from Sava Technologies's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Sava says its microsensor is roughly ten times shorter than filaments used in conventional continuous glucose monitors and was designed for high-volume manufacturing. The Ascensia partnership adds established clinical, payer and distribution channels in more than 90 countries.
Sava enters a continuous-glucose-monitoring market led by Abbott and Dexcom, with Medtronic and Senseonics also active. Its potential differentiation is a shorter minimally invasive sensor and a broader multi-biomarker platform, but regulatory clearance, manufacturing yield and real-world accuracy remain decisive.
-
Abbott incumbent
Global CGM leader through the FreeStyle Libre product family.
-
Dexcom incumbent
Major continuous glucose monitoring platform with broad clinical adoption.
-
Medtronic incumbent
Diabetes technology incumbent integrating CGM with insulin delivery.
-
Senseonics direct
Develops implantable long-duration continuous glucose monitoring systems.
Notable stories
- The Series B and Ascensia distribution agreement connect financing with a defined European commercialization route.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Sava Technologies's financing or category context.
FAQs about Sava Technologies
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.